← All trials
NCT03949764
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2019
- Primary completion
- Aug 31, 2022
- Completion date
- Jul 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KentuckyLead sponsor
- Gilead SciencesCollaborator
- National Cancer Institute (NCI)Collaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- University of KentuckyCollaborator
- University of KentuckyOverall official - principal investigator
- University of KentuckySponsor investigator
- University of BristolCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.